In this engaging forum, experts will open up about the challenges they face and share their experiences with optimizing care for early and end stage HF patients. A focus will also be placed on the practical implications and clinical relevance of the updated Canadian Cardiovascular Society Guidelines (CCS) / Canadian Heart Failure Society (CHFS) HF guidelines presented at this year’s Canadian Cardiovascular Congress.
This eXtract video features key information from the American College of Rheumatology (ACR) Convergence 2020. This quick tour with an expert focuses on extended follow-up data from the SELECT program—specifically the safety, efficacy, and durability of targeted oral JAK inhibitors. Longer follow-up data with these oral agents confirms that they offer a sustained advantage over injectable TNF inhibitors with no new safety concerns.
In Canada, about one-fifth of ischemic strokes are attributed to atrial fibrillation (AF). Consequently, both primary and secondary stroke prevention among patients with AF are critical. This program will examine the proper use of non-vitamin K oral anticoagulants (NOACs), as well as common reasons for improper anticoagulation. Dr. Wein will examine the differences between the four available NOACs as they relate to dosing requirements, risk of drug-drug interactions, and selection based on patient profile characteristics.
Objective and subjective measures of disease severity play a role in determining the best treatment plan for a patient. This video will review metrics used to determine the most appropriate treatment plan, as well as the importance of shared decision-making between clinicians, patients, and their families.
When traditional, skin-directed therapies fail to bring symptom relief, a targeted agent can be considered to control disease flares. In this extract video, Dr. Jack will review the efficacy, safety, and tolerability of the first biologic approved for the treatment of AD, as seen in clinical studies.
New substudy data from the phase 3 ASCLEPIOS I and II trials expand evidence that a targeted therapy improves outcomes relative to an immunomodulatory therapy in first-line treatment of RMS. The principle that early use of the most effective therapy results in lower rates of progression whether measured clinically or by imaging of brain activity potentially alters the treatment paradigm. In the ASCLEPIOS trial, the safety and tolerability of the targeted therapy, ofatumumab, was comparable to the immunomodulatory comparator, teriflunomide.
New findings drawn from substudies of the pivotal EXPAND trial and the extension study provides further evidence that protection against disability and cognitive decline is optimized with early treatment initiation. Among the new data, the favorable remyelinating effect of siponimod provides a foundation for understanding the major protection demonstrated against disability progression and cognitive decline.
When uncontrolled, atopic dermatitis (AD) can impose a large clinical burden on the patient—adversely affecting sleep, work, relationships, and overall daily living. This extract video will review the key drivers, symptoms, and coping mechanisms for AD; define adequate disease control and review systemic solutions for uncontrolled disease.
Large randomized clinical trials established non-vitamin K antagonist oral anticoagulants (NOACs) as the guideline-recommended standard of care for preventing stroke in patients with atrial fibrillation. More recently, the ETNA-AF Global Registry further substantiated the safety and efficacy of NOACs in an all-comer population including the elderly and frail.
Early nutrition plays a key role in the development of an infant’s gastrointestinal (GI) microbiota thus, also supporting the development of immunoprotective functions. Bioactive components found in human milk such as prebiotics, probiotics, and nucleotides are key factors in shaping the infant’s intestinal immune system, which makes up more than 80% of the body’s immune cells. The relationship between nutrition, gut microbiota and the immune system has led to recent advances in infant formula microbiota-targeted therapeutics. More specifically, this program will review the role of human milk oligosaccharides (HMOs) on the growth of gut microbiota and immune-modulation, and the systemic beneficial effects that they confer.